# Stefano Del Prato

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stefano-del-prato/

## Facts

| Field | Value |
| --- | --- |
| Citations | 57,548 |
| Field | Diabetes Treatment and Management |
| h-index | 102 |
| i10-index | 448 |
| Last Known Institution | University of Pisa |
| OpenAlex ID | https://openalex.org/A5019711625 |
| ORCID iD | https://orcid.org/0000-0002-5388-0270 |
| Works | 1,011 |

## Researcher papers

Showing 12 of 13.

- [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)](https://scholariq.org/papers/european-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice-5/)
- [Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)](https://scholariq.org/papers/management-of-hyperglycemia-in-type-2-diabetes-2022-a-consensus-report-by-the/)
- [Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and/)
- [Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future](https://scholariq.org/papers/pathophysiology-and-treatment-of-type-2-diabetes-perspectives-on-the-past/)
- [Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials](https://scholariq.org/papers/cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor-agonists-in-2/)
- [Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)](https://scholariq.org/papers/management-of-hyperglycaemia-in-type-2-diabetes-2022-a-consensus-report-by-the/)
- [Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations](https://scholariq.org/papers/metabolic-surgery-in-the-treatment-algorithm-for-type-2-diabetes-a-joint/)
- [COVID-19 in people with diabetes: understanding the reasons for worse outcomes](https://scholariq.org/papers/covid-19-in-people-with-diabetes-understanding-the-reasons-for-worse-outcomes/)
- [Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial](https://scholariq.org/papers/tirzepatide-versus-insulin-glargine-in-type-2-diabetes-and-increased/)
- [Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin](https://scholariq.org/papers/dapagliflozin-versus-glipizide-as-add-on-therapy-in-patients-with-type-2/)
- [Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial](https://scholariq.org/papers/effects-on-the-incidence-of-cardiovascular-events-of-the-addition-of/)
- [Review of methods for detecting glycemic disorders](https://scholariq.org/papers/review-of-methods-for-detecting-glycemic-disorders/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

## Researcher university

- [University of Pisa](https://scholariq.org/institutions/university-of-pisa/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.